Adjuvant Docetaxel in Nonmetastatic Prostate Cancer: The King Is Dead, Long Live the King!

Article Urology & Nephrology

Androgen Deprivation and Radiotherapy with or Without Docetaxel for Localized High-risk Prostate Cancer: Long-term Follow-up from the Randomized NRG Oncology RTOG 0521 Trial

Oliver Sartor et al.

Summary: This study provided long-term follow-up data on the combination therapy of androgen deprivation therapy (ADT) + external beam radiation therapy (EBRT) + docetaxel compared to ADT + EBRT in high-risk localized prostate cancer patients. After a median follow-up of 10.4 years, no significant differences in clinical outcomes were observed between the two treatment groups. These findings suggest that docetaxel may not be effective for high-risk localized prostate cancer.

EUROPEAN UROLOGY (2023)

添加到收藏夹

Article Urology & Nephrology

ARNEO: A Randomized Phase II Trial of Neoadjuvant Degarelix with or Without Apalutamide Prior to Radical Prostatectomy for High-risk Prostate Cancer

Gaetan Devos et al.

Summary: In this study, it was demonstrated that the combination of degarelix and apalutamide prior to radical prostatectomy significantly improved tumor response in high-risk prostate cancer patients compared to degarelix alone. These trial results provide a solid hypothesis-generating basis for neoadjuvant phase 3 trials to detect differences in long-term oncological outcomes.

EUROPEAN UROLOGY (2023)

添加到收藏夹

Article Oncology

Quality of Life in Men With Prostate Cancer Randomly Allocated to Receive Docetaxel or Abiraterone in the STAMPEDE Trial

Hannah L. Rush et al.

Summary: Patient-reported quality of life was better for patients receiving abiraterone acetate plus prednisone or prednisolone (AAP) alongside standard of care (SOC) compared to docetaxel plus SOC in locally advanced or metastatic hormone-sensitive prostate cancer, with particularly significant differences in the first year.

JOURNAL OF CLINICAL ONCOLOGY (2022)

添加到收藏夹

Article Medicine, General & Internal

Abiraterone acetate and prednisolone with or without enzalutamide for high-risk non-metastatic prostate cancer: a meta-analysis of primary results from two randomised controlled phase 3 trials of the STAMPEDE platform protocol

Gerhardt Attard et al.

Summary: The combination therapy of abiraterone acetate with prednisolone showed significantly higher rates of metastasis-free survival compared with ADT alone in men with high-risk non-metastatic prostate cancer. This combination therapy may be considered a new standard treatment for this patient population.

LANCET (2022)

添加到收藏夹

Article Oncology

Antizyme Inhibitor 1 Regulates Matrikine Expression and Enhances the Metastatic Potential of Aggressive Primary Prostate Cancer

Thomas Van den Broeck et al.

Summary: This study aims to investigate the molecular drivers of metastasis in patients with high-risk localized prostate cancer. Through a retrospective matched case-control study, it was found that an increase in AZIN1 gene expression is associated with metastatic recurrence in high-risk prostate cancer patients. Further research showed that AZIN1 knockdown can affect the proliferation and metastatic potential of prostate cancer cells.

MOLECULAR CANCER RESEARCH (2022)

添加到收藏夹

Article Oncology

Docetaxel for Nonmetastatic Prostate Cancer: Long-Term Survival Outcomes in the STAMPEDE Randomized Controlled Trial

Nicholas D. James et al.

Summary: This study found that adding docetaxel did not significantly improve metastatic progression-free survival in non-metastatic prostate cancer patients receiving long-term treatment. However, it did improve failure-free survival and progression-free survival without increasing late toxicity. There was no strong evidence for overall survival benefit.

JNCI CANCER SPECTRUM (2022)

添加到收藏夹

Article Urology & Nephrology